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It's a long way to Tipperary (1). The thesis you are now reading is the result of several 
years of hard scientific work, frequently interrupted by shorter and longer periods of 
not so hard work, strictly scientifically speaking. But not so scientifically speaking, 
clinical duty and the production of three boys, and the associated paternity leaves are 
also considered hard work by some. In the 6.5 years that has passed since I first started 
this project, I have experienced both the ups and downs of scientific work. There have 
been days of pure scientific joy, after getting a paper accepted or after having solved a 
particularly difficult problem. And I have very much enjoyed the opportunity to travel 
the world on scientific meetings together with colleagues that are also considered 
friends. But there have also been days of quite the opposite, after receiving yet another 
rejection, or experiencing a particularly long-drawn fit of writers block. Luckily, I'm 
already starting to forget the downs, and I'm very pleased to have experienced the ups. 
I am very grateful for the opportunity to go through with this project, and there are 
many people I would like to thank: 
First of all, I would like to extend my gratitude towards all the GenKOLS participants, 
and the supporting personnel that collected all the data before I had even joined the 
project. Without you and your efforts, none of this would have been possible. Thank 
you! 
Per Bakke, my brilliant and very likable main supervisor. I first came to know you 
when I did my “særoppgave” in medical school, and you were the one who lured me 
into the field of pulmonary medicine. Throughout this period you have always been a 
positive force, and you have managed to make me “see the light” when I saw nothing 
but obstacles. And even though your most frequent statement when we disagreed in 
our discussions was “Du har heeelt rætt!” (“You are absolutely right”), somehow we 
still mostly ended up doing things your way... Thank you for your patience and your 
constantly good mood. 
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Amund Gulsvik, Asger Dirksen, Einar Thorsen, Geir Egil Eide and Harvey Coxson 
were all my co-supervisors. Your expertise in the fields where I came up short has 
been very valuable. Thank you for all your input and efforts. 
Tomas Eagan, Sreekumar Pillai, Sanjay Sharma and Robert Jensen have all 
contributed as co-authors of one or more papers. Thank you. 
I would also like to thank all the other professors, post-doctors and research fellows 
that take part in the Respiratory Research Group at Haukeland University Hospital. 
You have contributed with valuable comments during research meetings, and you have 
been a most welcome social distraction during extended lunches and other 
arrangements. Thank you! 
Rune Nielsen needs special mention. He is both a good colleague and a very good 
friend. We have travelled to Tipperary together, and I'm not mad for you having beaten 
me to the finish line. It has been said that we are like an “old married couple”, but I 
think “almost brothers” is a more accurate term, and it is definitely more acceptable to 
our respective wives. Thank you for making the good parts of research even funnier, 
and the boring parts less so. 
Lungeavdelingen (The Pulmonary Dept.), under the friendly leadership of Alf-Henrik 
Andreassen and Kahtan Al-Azawy, has been my safe haven during all these years. 
Thank you for enduring my constantly changing roles, and for allowing me to use 50% 
of my clinical hours on research in the early phases of this project.  
I would also like to thank our collaborators at GlaxoSmithKline for financing the data 
sampling of the GenKOLS project, and Samarbeidsorganet Helse-Vest, for financing 
my fellowship years. 








1 – To quantify emphysema (%LAA, percentage Low Attenuation Areas) and airway 
wall thickness (AWT-Pi10, Airway Wall Thickness in a standardized airway with an 
internal perimeter of 10 mm) in ever-smoking COPD and non-COPD subjects using 
quantitative CT analysis, and to determine how these anatomic measures varied with 
gender, age and smoking habits. 
2 – To describe the relationship between respiratory symptoms of COPD and 
quantitative CT measures of emphysema and airway wall thickness, and to assess how 
these relationships interacted with COPD-status, gender, age and smoking history. 
3 – To examine the relationship between the diffusing capacity of the lung and 
quantitative CT measures of emphysema and airway wall thickness, and to assess how 
these relationships varied by COPD status, gender, age and smoking history. 
Methods 
The subjects included in the current study were all participants in the GenKOLS study, 
and constitute the approximate half of the GenKOLS population that received an 
optional CT scan. A total of 463 COPD subjects (65 % men) and 488 non-COPD 
subjects (53 % men) were included in this study. In paper I we excluded 57 non-COPD 
subjects (volunteers) from the analyses, and in paper III we excluded 175 COPD 
subjects and 63 non-COPD subjects from the analyses due to missing or invalid DLCO 
measurements. All included subjects were current or ex-smokers older than 40 years. 
They underwent spirometry (Vitalograph 2160), diffusing capacity tests 
(SensorMedics Vmax22D) and CT examination (GE LightSpeed Ultra), and 
completed multiple questionnaires, including an ATS questionnaire on respiratory 
symptoms. The CT images were quantitatively assessed (Emphylx-J software), giving 




1 – Median (25, 75-percentile) %LAA was 8.9 (2.8, 19.1) and 4.7 (1.5, 15.5) in male 
and female COPD subjects, and 0.71 (0.32, 1.58) and 0.32 (0.14, 0.84) in male and 
female non-COPD-subjects. %LAA was higher in ex-smokers and increased with 
increasing age and with increasing number of pack years. Mean (SD) AWT-Pi10 (mm) 
was 5.04 (0.30) and 4.74 (0.31) in male and female COPD subjects, and 4.88 (0.28) 
and 4.63 (0.25) in male and female non-COPD subjects. AWT-Pi10 decreased with 
increasing age in cases, and increased with the degree of current smoking in all 
subjects. 
2 – Both %LAA and AWT-Pi10 were independently and significantly related to the 
level of dyspnea among COPD subjects, even after adjustments for FEV1 in % 
predicted. AWT-Pi10 was significantly related to cough and wheezing in COPD 
subjects, and to wheezing in non-COPD subjects. Odds ratios (95% confidence limits) 
for increased dyspnea in COPD subjects and non-COPD subjects was 1.9 (1.5, 2.3) 
and 1.9 (0.6, 6.6) per 10 % increase in %LAA, and 1.07 (1.01, 1.14) and 1.11 (0.99, 
1.24) per 0.1 mm increase in AWT-Pi10, respectively.  
3 – Multiple linear regression analyses showed significant associations between DLCO 
and both %LAA and AWT-Pi10 in the COPD group. The adjusted regression 
coefficients (SE) for DLCO were -1.15 (0.11) mmol · min-1 · kPa-1 per 10% increase in 
%LAA and 0.08 (0.03) mmol · min-1 · kPa-1 per 0.1 mm increase in AWT-Pi10, and the 
adjusted R2 of the models were 0.65 and 0.49, respectively. 
Conclusions 
1 – There were significant differences between COPD and non-COPD subjects in 
quantitative CT measures of emphysema and airway wall thickness. Gender, age and 
smoking history also had strong effects on these quantitative CT measures and must be 
considered when comparing quantitative CT studies. 
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2 – Quantitative CT measures of emphysema and airway wall thickness were 
significantly and independently associated with respiratory symptoms, and may be 
used to explain the presence of respiratory symptoms beyond the information offered 
by spirometry.  
3 – Quantitative CT measured emphysema was highly related to both diffusing 
capacity and diffusing coefficient in COPD subjects, and this relationship was even 
stronger in men. There was also a positive, but not equally strong, relation between CT 
measured airway wall thickness and diffusing capacity, and this was contrary to our 
hypothesis that there would be no relationship between airways and diffusing capacity. 
Both CT measures provide valuable information about the lungs not readily available 
from spirometry and diffusing capacity alone, but the modest explained variation 








Terms and abbreviations 
%LAA Percentage Low Attenuation Areas. A measure of the degree of 
emphysema. Indicates the relative amount of lung voxels that has a 
density less than the given cut-off. The most frequently used cut-off is 
-950 HU (%LAA-950), but other cut-offs are also in use (e.g. -910 
HU, -856 HU, etc). If nothing else is specified, %LAA should be 
interpreted as %LAA-950. 
AWT-Pi10 A standardized measure of Airway Wall Thickness at an Internal 
Perimeter of 10 mm. This measure is calculated by plotting the square 
root of the measured wall area against the internal perimeter of each 
individually measured airway, and then using the resulting regression 
line to calculate the resulting square root of the wall area of a 
«theoretical airway» with an internal perimeter of 10 mm. 
COPD Chronic Obstructive Pulmonary Disease 
CT Computed Tomography 
DICOM Digital Imaging and Communications in Medicine. A standard for 
distributing and viewing any kind of medical image. 
DLCO Diffusing capacity of the Lung for carbon monoxide 
DLCO /VA Diffusing capacity of the Lung for carbon monoxide divided by the 
estimated alveolar volume. The equivalent of KCO. 
FEV1 Forced Expiratory Volume in one second 
FVC Forced Vital Capacity 
GenKOLS Genetic COPD study 
GOLD Global initiative for Obstructive Lung Disease 
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HCRHS Hordaland County Respiratory Health Survey 
HU Hounsfield Units. A density scale, ranging from -1000 HU (the 
equivalent of air) to +1000 HU (the equivalent of dense bone). Water 
has a density of 0 HU. 
HUH Haukeland University Hospital 
Inflation 
Level 
CT measured lung volume divided by the predicted TLC 
IVC Inspired Vital Capacity 
kVp Kilo-Volt peak. Beam energy. 
mAs Milliampere seconds. The product of the tube current and time. 
MRCDS Medical Research Council Dyspnea Scale 
OR Odds Ratio 
Pack-years Number of cigarettes smoked per day divided by 20, and multiplied 
with the number of years smoked. 
Pi  Internal perimeter 
PI type Protease Inhibitor type. Used to classify different forms of A1AT-
defiency 
RV Residual volume 
SOHAS Second Oslo and Hordaland Asthma Survey 
TLC Total Lung Capacity 
VA Estimated Alveolar Volume 
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Voxel A three dimensional pixel, or a box. The size of a voxel is decided by 
the resolution of the image and the slice thickness. A voxel is the 
smallest part of the lung where individual density measurements can 
be made using quantitative CT. 
WA% Wall Area Percent. The percentage of the measured total airway area 
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Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity 
and mortality throughout the world. It was ranked as the sixth most common cause of 
death worldwide in 1990, and is projected to become the third leading cause of death 
by 2020 (2). 
The main characteristic of COPD is chronic airflow obstruction, and the predominant 
symptoms are chronic and progressive dyspnea, cough, and sputum production. COPD 
is usually caused by cigarette smoking, which is the best-studied risk factor, but 
several other risk factors have been identified (2). These factors include environmental 
tobacco smoke (passive smoking), indoor and outdoor pollution, occupational dusts 
and chemicals, and several genetic risk factors, including α1-antitrypsin deficiency.  
Previous COPD definitions have distinguished between different types of COPD, and 
as illustrated in Figure 1, there is a considerable overlap between the different types of 
COPD (3, 4). 
Asthma is a chronic inflammatory disorder of the airways and cannot be classified as 
COPD as long as the airflow obstruction is completely reversible (5). Chronic 
bronchitis is defined by a chronic productive cough for three months in each of two 
successive years in a patient in whom other causes of chronic cough have been 
excluded (4). Emphysema is defined by abnormal and permanent enlargement of the 
airspaces that are distal to the terminal bronchioles, accompanied by destruction of the 
airspace walls, and without obvious fibrosis (4). As illustrated by the Venn diagram, 
all three conditions may exist independently or concurrently, and they may or may not 




Figure 1 Non-proportional Venn diagram showing subsets of patients with chronic bronchitis, 
emphysema, and asthma (black circles). The subsets defined as COPD are shaded gray. The numbers 
simply indicate the different subsets, and will not be referred to in this thesis. (Taken from ATS. 
Standards for the diagnosis and care of patients with COPD, 1995 (3)) 
 
It has become clear that COPD is a complex and heterogeneous disease, and that the 
described Venn diagram should not be taken too literally (6). It has been a useful way 
of illustrating the different components of COPD, but it is by no means complete. For 
instance, it does not include small airway disease, while most of the airflow 
obstruction is due to reduced airflow in the small conducting airways (7). The 
discussion about how COPD should be divided into various subgroups or phenotypes 
is ongoing in the scientific community (8). 
Today, the most widely used and accepted COPD guidelines is The Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) (2). GOLD defines COPD as follows: 
"COPD is a preventable and treatable disease with some significant extrapulmonary 
effects that may contribute to the severity in individual patients. Its pulmonary 
component is characterized by airflow limitation that is not fully reversible. The 
airflow limitation is usually progressive and associated with an abnormal 
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inflammatory response of the lungs to noxious particles or gases." The previous 
distinction between asthma, emphysema and chronic bronchitis is not included in the 
current GOLD definition. Instead it focuses on a not fully reversible airflow 
obstruction, and specifies that the chronic airflow limitation characteristic of COPD is 
caused by a mixture of small airway disease (obstructive bronchiolitis) and 
parenchymal destruction (emphysema). The relative contributions of these subtypes 
vary from person to person. 
The chronic airflow limitation in COPD is best measured by spirometry, because this 
is the most widely available, reproducible test of lung function. The GOLD guidelines 
recommend that COPD is classified into four stages of severity based on spirometry, 
ranging from mild to very severe (Table 1). 
 
Table 1 Classification of COPD severity based on post-bronchodilator FEV1 and FVC 
Stage I: mild FEV1/FVC < 0.70 
FEV1  80% predicted 
Stage II: moderate FEV1/FVC < 0.70 
50% FEV1 < 80% predicted 
Stage III: severe FEV1/FVC < 0.70 
30% FEV1 < 50% predicted 
Stage IV: very severe FEV1/FVC < 0.70 
FEV1 < 30% predicted or FEV1 < 50% predicted plus 
chronic respiratory failure 
 
This classification provides a simple and useful clinical tool for both diagnosis and 
treatment of COPD, but the cut points are not clinically validated. Especially the use of 
the fixed FEV1/FVC-ratio of 0.70 has been debated, and it has been shown that the use 
of this fixed ratio can lead to an over-diagnosis of COPD in the elderly (9).  
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The FEV1 % predicted, as reflected in the four GOLD stages, defines the severity of 
COPD, but to the individual patient the respiratory symptoms are more important. The 
characteristic symptoms of COPD are chronic dyspnea, cough and sputum production. 
The level of dyspnea also corresponds reasonably well to the reduction in FEV1, but 
chronic cough and sputum production may precede the development of airflow 
limitation by several years. And conversely, the patients may develop significant 
airflow obstruction without any cough or sputum.  
Hence, spirometry is not the only instrument needed to assess and monitor COPD. A 
thorough physical examination and a detailed medical history, including risk factors, 
respiratory symptoms and co-morbidities are important. A reversibility test may be 
useful, but cannot reliably differentiate COPD from asthma (10). Arterial blood gas 
measurements may be important in the more severe stages of COPD that has started to 
develop respiratory failure. Genetic testing may explain COPD in never-smokers with 
α1-antitrypsin deficiency. Lung diffusing capacity may help differentiate between 
COPD and other interstitial lung diseases, and may also say something about the 
predominant subtype of COPD (emphysema or small airway disease). Chest X-ray and 
CT thorax are also widely used, and will be discussed in the next section.  
Radiological approaches to COPD 
X-rays was discovered by W.C. Roentgen in 1895. Initially its medical use was limited 
to identifying bone structures, but since then it has been increasingly used as a medical 
diagnostic method. Conventional plain X-ray of the chest has for many years been 
used to assess respiratory diseases, including COPD. An abnormal chest X-ray is 
seldom diagnostic in COPD unless obvious bullous disease is present, but it can be 
valuable in excluding alternative diagnoses and establishing the presence of significant 
comorbidities, such as cardiac failure and lung tumours.  
Conventional X-ray technology is limited in that the image it produces is a shadow of 
all the structures in the body that the X-rays pass through. All these structures become 
superimposed on each other as they are projected on the film or X-ray sensor, and as a 
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result each single plane blurs the others. To avoid this, Mayer proposed a method 
known as tomography in the early 1900s, and this was further refined by Vallebona, 
Bocage and Grossmann (11). The idea was based on the principles of projective 
geometry. By moving the X-ray tube and the film (inter-attached by a rod) 
synchronously and in opposite directions, one could produce an image which was 
sharper in the focal plane (corresponding to the rod’s pivot point), while the images 
from the other superimposed planes would be more blurred. Although tomography was 
limited by the fact that the absence of blurring occurred in one plane only, it continued 
to be an important part of radiologic diagnostics for many years, until the development 
of computed tomography. 
The mathematical theory behind computed tomography was also developed in the first 
half of the 20th century (H.A. Lorentz 1905, J.H. Radon 1917). It was shown that the 
distribution of material properties in an object layer can be calculated if the integral 
values along any number of lines passing through the same layer are known. But it was 
first in the 1970s the development of modern computer technology and the transverse 
axial scanning method made possible a new approach. And in 1979, G.N. Hounsfield 
and A.M. Cormack were awarded the Nobel Prize in Medicine in recognition of their 
important role in the development of computed tomography. 
Since the arrival of the first clinical CTs in the 1970s, there has been a tremendous 
development. The first single-slice units could only do head-scans, had low resolution 
(80x80 pixels) and were very slow in terms of both scanning and data processing. 
Today’s CTs can scan the whole body, have a much higher resolution and are much 
faster using multi-slice (128) and dual-source technology. As a result of this ongoing 
development, the newest CTs can scan the whole thorax well within one breath-hold, 
and using much lower radiation doses than before.  
With regard to COPD, a CT of the chest is not routinely recommended. However, 
when there is doubt about the diagnosis of COPD, a high-resolution CT scan might 
help in the differential diagnosis. It is also an important tool to determine the amount 




COPD is characterized by abnormal lung function and structure. Pulmonary function 
testing, and spirometry in particular, has evolved to become a reliable and safe method 
to measure the severity and progression of the impaired lung function associated with 
COPD. A similar assessment of the anatomic and structural changes associated with 
COPD has until recently not been possible.  
Conventional CT uses the density measurements from the scan to produce images that 
are available for interpretation by a radiologist, yielding semi-quantitative data. The 
advent of quantitative CT of the chest has made it possible to use the same density 
measurements to produce quantifiable data on airways and parenchyma. Instead of 
categorizing emphysema as mild, moderate or severe based on a radiologist’s 
assessment, quantitative CT yields a more accurate and precise measure of lung 
density and emphysema on a continuous scale. Similarly, instead of a radiologist’s 
description of the presence or absence of bronchiectasis or slightly thickened airway 
walls, quantitative CT accurately measures the dimensions of both lumen and wall in a 
large number of airways throughout the lungs.  
Over the last few years there has been a considerable development of the technical and 
methodological aspects of quantitative CT and a growing number of clinical studies 
have used quantitative CT in their assessment of COPD. But unlike spirometry, 
quantitative CT has not been fully standardized. There is no general consensus on 
which of the many possible quantitative CT algorithms or measures that are best at 
quantifying the airway and parenchymal lesions that are characteristic of COPD. With 
regard to emphysema, there are several different density cut-offs that are used to 
calculate the percentage of low attenuation areas, and the most frequently used is -950 
HU. In addition, many centres measure the density at a given percentile instead, and 
the most frequently used is the 15th percentile. With regard to the airways, there are 
also many different approaches, focusing on both wall area and wall thickness, and 




Relevant literature prior to the current study 
In 1988 Gould et al. (fifth percentile) and Müller et al. (“density mask” at -910 HU) 
described each their quantitative CT technique, and found good correlation with 
morphometric measurements of emphysematous pathologic lung sections (12, 13). 
They also demonstrated that the quantitative lung density measurements were 
correlated with airflow limitation (FEV1) and diffusing capacity (13-15). In 1996 
Gevenois et al. showed that a threshold cut-off value of -950 HU had the best 
correlation with extent of emphysema (16). Other groups pursued the percentile 
method, and found that 15th percentile provided the best estimate of the extent of 
emphysema, especially in subjects with α1-antitrypsin deficiency and in longitudinal 
studies (17, 18). These two methods of assessing the extent of emphysema are 
basically not very different, as they both present the same data in slightly different 
ways, and there are no big controversies between these two approaches. 
The quantitative assessment of airways, on the other hand, has generated more 
controversy (19). In 1997 McNitt-Gray et al. found that airways could be accurately 
measured using a density cut-off of -500 HU (20), and this was followed up King et al. 
in 2000, using a threshold of -577 HU (21). However, while this method was very 
good at assessing the airway lumen, it was not very good at assessing the airway wall. 
The development of the “full width at half maximum” technique solved some of these 
problems, but has a tendency to overestimate the airway wall area and underestimate 
the lumen area (22, 23). To overcome these obstacles, several other approaches have 
been developed, including the “maximum-likelihood method” and the “score-guided 
erosion algorithm”, but no single method has emerged as superior to the others (19). A 
frequently used way to present the airways measurements is the Wall Area Percent 
(WA%), which is the percentage of the total airway area that is wall. In 2000 Nakano 
et al. showed that WA% in the right apical segmental bronchus correlated with FEV1, 
FVC and RV/TLC (23), and later Nakano et al. showed that WA% measured by CT 
correlated with the wall area measured histologically in the same subjects (24). These 
findings indicated that the airflow limitation in the small airways (< 2 mm), that 
cannot be measured by CT, can be assessed using the larger airways (>2 mm) that are 
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available to quantitative CT measurements. There is however a potential problem with 
WA%. The smaller the airway, the larger the relative wall area (WA%). To avoid this 
potential bias, Nakano also plotted the square root of the airway wall area against the 
internal perimeter of that airway for both CT and histologic measurements, and found 
good correlation between the two (24).  
Thus, at the start of the current study, there were several studies showing that different 
quantitative CT measures correlated well with both anatomic and functional measures 
of the lung. But the majority of these studies had small sample sizes and was focused 
on the methodological aspects. There was limited knowledge on how these 
quantitative CT measures varied with gender, age and smoking history, and how they 
related to pulmonary function and respiratory symptoms, but some data had been 
published: 
 
Gevenois et al. looked at the effects of age, sex, lung size and hyperinflation on CT 
lung densitometry in 1996 (25). They found only a small age-effect, and no gender-
effect, but there were only 42 healthy subjects included in the study. In a longitudinal 
follow-up study of 83 subjects in 2000, Soejima et al. also found that quantitative CT 
measured emphysema increased with age, and more so in smokers, but the study was 
too small to assess the gender effect (26). Nakano et al. found that quantitative CT 
measurements of both airways and emphysema correlated with pulmonary function 
(spirometry and diffusing capacity) in 114 smokers, but did not take age, gender or 
smoking into account (23). In 1999 Park et al. reported that emphysema assessed using 
the -950 HU threshold correlated well with FEV1 and DLCO, and better than the -910 
and -900 HU thresholds (27). This study comprised 60 subjects, and was also too small 
to assess gender, age and smoking effects. In 2001 Dowson et al. reported that 
quantitatively assessed emphysema (-910 HU) correlated with health status assessed 
by St. George’s respiratory questionnaire in 125 subjects with α1-antitrypsin deficiency 
(28). No studies had looked directly on the relationship between quantitative CT and 
respiratory symptoms to give quantitative CT measures a clinical correlate. 
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The above mentioned references are not complete, but illustrate the limited available 
knowledge concerning quantitative CT assessment of emphysema and airways when 
this study was initiated. While there was reasonable agreement that quantitative CT 
measures were correlated with pulmonary function, the technique was not 
standardized, and there were many unsolved questions (29): 
 Disagreement on optimal approaches/techniques, especially with regard 
to airways 
 No established normal reference values 
 Limited validation against phenotypic expressions of COPD other than 
spirometry 
 Lack of large studies to assess the effect of gender, age and smoking 
history in both COPD patients and healthy subjects 
The current study was at the time of initiation the largest available study sample with 
quantitative CT data on lung density and airway dimensions. We hypothesized that 
gender, age and smoking history would have significant effects on the quantitative CT 
measures of emphysema (%LAA) and airway wall thickness (AWT-Pi10). We also 
hypothesized that %LAA would be strongly related to dyspnea score and DLCO, and 








Aims of the study 
 
The objectives of this thesis were: 
1) To quantify emphysema and airway wall thickness in ever-smoking COPD and 
non-COPD subjects using quantitative CT analysis, and to determine how these 
anatomic measures varied with gender, age and smoking history. 
 
2) To describe the relationships between respiratory symptoms of COPD and 
quantitative CT measures of emphysema and airway wall thickness, and to 
assess how COPD-status, gender, age and smoking history interacted with these 
relationships. 
 
3) To examine the relationship between the diffusing capacity of the lung and 
quantitative CT measures of emphysema and airway wall thickness, and to 








Materials and methods 
Study design and study population 
The subjects included in the current study were all participants in the GenKOLS-study, 
and constitute the approximate half of the GenKOLS population (951 of 1909) that 
received an optional CT scan. 
The GenKOLS-study was performed at Haukeland University Hospital (HUH) 
between 2003 and 2005, and was a case/control study designed to look for genetic 
associations with COPD. GenKOLS recruited potential cases and controls from four 
different sources: 
 Hordaland County Respiratory Health Survey (HCRHS) 
 Second Oslo and Hordaland Asthma Survey (SOHAS) 
 Haukeland University Hospital COPD registry (HUH COPD registry) 
 Volunteers 
HCRHS is a large epidemiological cohort study that was performed in Hordaland 
County, initiated in 1985, and followed up in 1996/97 (30, 31). All subjects from 
HCRHS that were still living in Bergen and surrounding communities in 2002 were 
invited to participate in another follow-up of the HCRHS. The HCRHS subjects who 
were eligible for inclusion in GenKOLS were also invited to participate in GenKOLS. 
SOHAS is a cross-sectional population study that was performed in the city of Oslo 
and Hordaland county in 1998 (32). The HUH COPD registry comprised all patients 
registered with a diagnosis of COPD or emphysema in the hospital records between 
1997 and 2005. Volunteers were people who contacted the study staff and expressed 















































































































































































































































































































The table above (Table 2) shows how many subjects from each source that were 
invited, how many that attended a clinical examination at HUH (GenKOLS screening) 
and finally how many that were included in GenKOLS and subsequently in the 
quantitative CT study. 
Inclusion and exclusion criteria 
Inclusion criteria 
- Able and willing to sign an informed consent form. 
- Age 40 years. 
- Current or ex-cigarette smoker, minimum 2.5 pack years. 
- No evidence of severe 1-antitrypsin deficiency (ZZ, Z Null, Null-Null, or SZ) 
assessed by PI type. 
- Caucasian self reported.  
- Cases:  Diagnosed COPD, GOLD II or worse. 
            FEV1/FVC < 0.7, FEV1 < 80% (post bronchodilator) 
- Controls:  Not diagnosed with COPD.  
      FEV1/FVC > 0.7, FEV1 > 80% (post bronchodilator) 
Exclusion criteria 
- Unable to give informed consent. 
- Severe anaemia as defined by haemoglobin of 9.0 g/dl. 
- Known HIV, hepatitis B or C infection. 
- Blood transfusion received within last 4 weeks. 
- Chronic pulmonary disorder other than COPD (e.g., lung cancer, sarcoidosis, 
active tuberculosis, and lung fibrosis). Inactive tuberculosis and previous diagnosis 
of asthma were not an exclusion criterion. 
- Status post-lung or other organ transplantation. 
- Status post-lung volume reduction surgery. 
- Taken antibiotics for respiratory disease within 1 month or have had a respiratory 
infection within 6 weeks of the visit. 
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To be included in the study the subjects had to fulfill all inclusion criteria and no 
exclusion criteria. However, subjects fulfilling transient exclusion criteria such as a 
recent respiratory infection or low hemoglobin were eligible for a reconsideration of 
inclusion at a later date. 
Study sequence and data collection 
First, the potential study participants from each source were identified. Then, the 
volunteers and the subjects originating from SOHAS and the HUH COPD registry 
were screened by telephone interview (Appendix A), to ensure that they were aged 40 
years or older, that they were current or ex-smokers with at least 2.5 pack years and 
that they were willing to participate in the study. During the telephone interview they 
were also informed about the GenKOLS study, and if they were willing to participate 
they were given an appointment for a screening visit and clinical examination at HUH. 
Those willing to participate were subsequently sent a letter (Appendix B, C) 
containing a confirmation of the appointment, a screening consent form, a screening 
questionnaire and a description of the GenKOLS study. Eligible subjects (age>40 
years, minimum 2.5 pack-years) originating from HCRHS were not screened by 
telephone, but sent a letter (Appendix B, C) directly containing a description of the 
GenKOLS study and why they were invited, a screening consent form, a screening 
questionnaire and an appointment for a screening visit and clinical examination at 
HUH. 
At the screening visit, an extensive description of the study was given to all attending 
participants, and informed written screening consent was signed. The study staff 
ensured that the screening questionnaire was correctly completed, and recorded 
weight, height, waist hip measurements, vital signs and breath sounds on all 
participants. Then pre- and post-bronchodilator spirometry was performed on all 
participants. 
Based on the post-bronchodilator spirometry and the screening questionnaire, the 
subjects were then identified as cases or controls in the GenKOLS study, according to 
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the inclusion and exclusion criteria described. The participants originating from 
HCRHS that did not meet these criteria were still offered to be included in the 
longitudinal follow-up of HCRHS using the already obtained screening data. 
The subjects that were eligible for inclusion as cases or controls then signed a written 
case-control study consent form (Appendix D), and completed a larger case-control 
questionnaire (Appendix E). Then measurements of diffusing capacity and whole body 
impedance were performed, and blood samples were drawn for biochemical and 
genetic analyses. The cases and controls were also offered an optional high resolution 
CT scan for quantitative analyses, to be taken the same day or on a separate later visit. 
This optional scan was offered until a total of approximately 1000 CTs were acquired, 
equally distributed between cases and controls. 
Questionnaires 
All invited subjects were sent the short screening questionnaire (Appendix C). Only 
included cases and controls were asked to complete the more extensive case-control 
questionnaire. This questionnaire consisted of 35 pages and more than 200 questions 
concerning demographics, medical history, family history, smoking history, 
occupational history and more. The case-control questionnaire is too large to be 
printed in this thesis. Instead, only the questions that were actually used in papers I-III 
are given in this thesis. The selected questions from the case-control questionnaire 
concerned demographics, smoking history, respiratory symptoms and co-morbidities. 
The exact wording of these questions (not demographics) is given in Appendix E, both 
in English and Norwegian translation. 
Lung function measurements 
Spirometry 
Spirometric measurements were recorded at the screening visit, using a Vitalograph 
2160 Gold Standard Plus (Appendix F), and according to the American Thoracic 
Society standards (3). All testing equipment was calibrated daily using a Vitalograph 1 
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liter precision syringe, and a log of the calibration results was maintained. Local 
reference values for FEV1 and FVC were used (33). 
Subjects were assessed at least 6 weeks after any respiratory infection. Subjects were 
not asked to withhold regular medication (including bronchodilators), but recent use of 
bronchodilators was recorded. The pulmonary function tests were supervised by 
trained technicians, and the subjects were sitting upright using a nose clip to avoid 
leakage. 
Three acceptable forced expiratory maneuvers were recorded, and the highest pre 
bronchodilator FVC and FEV1 values were selected. After the baseline spirometry, the 
subjects were given 400 µg of Ventoline (salbutamol) via a metered dose inhaler and 
an Aerochamber spacer. 30 minutes after the administration of salbutamol, another 
three acceptable forced expiratory maneuvers were recorded, and the highest post 
bronchodilator FVC and FEV1 values were selected. These post bronchodilation 
measurements were used for inclusion/exclusion and GOLD classification of the 
participants, and also as an adjustment factor in the multiple regression analyses. 
Diffusing capacity 
The single breath diffusing capacity of the lung for CO (DLCO) was also recorded at 
the screening visit. We used a SensorMedics Vmax Spectra 22D (Appendix G) for these 
measurements, and the system was calibrated daily. We followed the recommended 
ATS guidelines (34) for DLCO measurements with one exception. This concerned the 
criterion that IVC should not be less than 90% of the largest previously measured 
FVC, and this topic will be discussed later under Methodological Aspects.  
We used a gas mixture of 0.3% carbon monoxide, 0.3% acetylene, 0.3% methane, 
21% oxygen and nitrogen. Estimated alveolar volume (VA) was measured from the 
single breath dilution of methane, and the diffusion coefficient (DLCO/VA) was 
calculated by dividing DLCO by VA. Local reference values for DLCO, VA and 
DLCO/VA (35) were used. 
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The subjects were sitting upright and using a nose clip during the measurements, and 
the tests were supervised by trained technicians. After 4-5 registered tidal volumes, the 
end-expiratory baseline was determined, and the subjects were then asked to exhale 
fully. When full exhalation was reached, the subjects made a rapid maximal inhalation, 
and continued to hold their breath for 10 seconds, before exhaling rapidly. Up to 4 
maneuvers were performed in order to obtain 2 error free tests, and there was a 
minimum interval of 4 minutes between each maneuver.  
Computed tomography 
CT image acquisition 
The high resolution CT images were acquired at Haukeland University Hospital using 
a GE LightSpeed Ultra CT scanner (Appendix H). The images were taken at 
suspended full inspiration, and without spirometric gating. A high resolution axial scan 
was performed, using 120 kVp and 200 mAs, and a slice thickness of 1.25 mm taken 
at 20 mm intervals from the apex to the base of the lungs. The images were 
reconstructed using a low spatial frequency algorithm (standard) for the lung density 
measurements, and using a high spatial frequency algorithm (bone) for the airway 
measurements. The smallest Field Of View that included both lungs was used. The CT 
images were then stored on Magnetic Optical Disks (DICOM 3.0 format), and shipped 
to Vancouver, Canada, for quantitative assessment. 
A local radiologist (at HUH) reviewed all CT images for signs of clinically significant 
abnormalities. A total of 118 subjects were referred for a repeated CT scan 
(contiguous) due to such abnormalities, and then through the national health care 
service for further follow-up. The majority of these abnormalities proved to be 
harmless, but 3 subjects were diagnosed with lung cancer as a result of this process. 
Quantitative assessment 
The quantitative analysis of the CT images was performed by the iCapture Centre in 
Vancouver, BC, Canada, under the supervision of Dr. Harvey Coxson (UBC James 
Hogg Research Centre and Vancouver General Hospital). 
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All the CT images were first assessed by two independent radiologists, yielding semi-
quantitative data on the extent, distribution and type of emphysema, as well as the 
possible presence of bronchiectasis. The radiologists also reported any clinically 
significant abnormalities, and if these were not already discovered by the local 
radiologist at Haukeland University Hospital, the subjects in question were referred 
through the national health care service for further follow-up. These semi-quantitative 
data has not been the focus of this thesis. 
The DICOM 3.0 format CT image data was imported into Emphylx-J (36), a graphics-
based lung analysis program for quantitative analysis of thoracic CT scans developed 
by the iCapture Centre.  
The software automatically segmented the lungs from the chest wall, the trachea and 
central airways and the mediastinum using a modified border tracing algorithm with 
prior position knowledge (37). This segmentation was shown visually to the operator, 
who could check the segmentation slice by slice. Any segmentation errors could then 
be corrected by the operator by adding, subtracting or reclassifying the segmented 
areas. After the correct lung segmentation was established, the software used the X-ray 
attenuation values from the CT images to calculate the lung density, lung volume, lung 
mass, regional expansion and surface area to volume ratios. Based on operator input, 
the software also calculated the percentage of low attenuation areas with a density 
lower than a chosen density cut-off (density mask). All of the above values were 
calculated for each slice, for each lung and for the total lung. 
A custom version of Emphylx-J was also used for the quantitative airway analyses. 
The operator had to review each slice and manually identify airways that were cut in 
cross-section (short to long axis greater than 2:3). A seed point was placed in the 
lumen of each identified airway, and the software automatically computed the inner 
and outer limits of the airway walls using the Full Width At Half Maximum algorithm 
(24). This algorithm draws 64 radial lines from the seed point and measures the X-ray 
attenuation along these lines. Then it chooses the two points where the X-ray 
attenuation is half of the maximum attenuation value measured along that line as the 
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inner and outer limit of the actual airway. After the airway wall limits had been 
established, the software calculated the inner and outer perimeter of each identified 
airway wall, as well as the area of the lumen and the area of the wall itself. To reduce 
the technical errors associated with very small airways, only airways with an internal 
perimeter > 6 mm were included. The number of identified airways was also recorded, 
but due to the axial scanning method that was used (and not helical) we had no way of 
tracing the airways and classifying them into generations. 
Quantitative CT measures used in this study 
The extent of emphysema was assessed using the density mask method described 
above, to get the percentage of lung voxels with a density lower than a certain 
threshold. We used the term %LAA (percentage low attenuation areas) to describe 
these low density regions of the lung. We used -950 Hounsfield Units (HU) as the 
primary cut-off (%LAA-950), and when nothing else is specified, %LAA should be 
interpreted as %LAA-950. The -950 HU cut-off has been shown to be appropriate for 
this CT acquisition technique (16, 38), but several other cut-offs are also commonly in 
use. For comparison, we also performed the density mask analyses using -910 HU and 
-856 HU as cut-offs, yielding %LAA-910 and %LAA-856. Another frequently used 
measure of the extent of emphysema is the 15th percentile density, which is the density 
(given in HU) at which 15% of the lung voxels have a lower density. This measure 
was also calculated from our material. 
The airway wall thickness (AWT) is often expressed as the Wall Area Percent 
(WA%), which is the percentage of the whole airway area that is wall (and not lumen). 
We calculated WA% from this material, but there is a potential problem with this 
measure: With increasing airway generations, the airways get smaller, and the smaller 
the airway, the larger the relative wall area. To avoid the potential bias issues 
surrounding different distribution of airway sizes between subjects, a standardized 
measure for AWT was derived for each subject by plotting the square root of the 
airway wall area against the internal perimeter of each measured airway (Figure 2). 
The resulting regression line was used to calculate the square root of the wall area for a 
‘theoretical airway’ with an internal perimeter of 10 mm (AWT-Pi10). Although CT 
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measured AWT tends to be overestimated compared to histologic AWT, especially in 
small airways, there is a good correlation between histologic and CT measurements 
when the square root of the wall area is plotted against the internal perimeter of the 
airway (24).  
 
Figure 2 The calculation of AWT-Pi10. The square root of the wall area of each measured 
airway (√WA) was plotted against the internal perimeter (Pi) of that airway. This was 
performed separately for each subject. From the resulting regression line, a standardized 




All data from the questionnaires and clinical tests were initially recorded on paper, and 
the paper records were kept in a locked archive facility. The data from the paper 
records were later punched into an online database by the local study staff, and 
continuous simple error-checks were applied to reveal and correct punching errors. 
Examples of this were out of range values and missing values. The online database 
(GenNet, operated by GSK) was password-protected, and access was only given to 
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selected members of the local study staff and selected members of the GSK staff. The 
online database was anonymized and contained no identifiable data except for a unique 
study ID number. Only the local project manager (Amund Gulsvik) had access to the 
data key that linked this ID with the subjects’ name and date of birth.  
After the data sampling phase was completed, an external monitoring agency checked 
the quality of the sampled data. The paper records from 5 % of the subjects (50 cases 
and 50 controls) were randomly chosen and re-punched, and the results were checked 
against the information stored in the online database. The agency concluded that there 
was good agreement between the paper records and the information stored in GenNet, 
and noted only a few discrepancies that were mostly related to smoking history. There 
were 25 observed smoking related discrepancies among these 100 subjects. But each 
subject answered a total of 36 smoking related questions, yielding a low discrepancy 
rate (25/3600). The observed discrepancies were later corrected in GenNet. 
Then, extensive inconsistency analyses were run manually using Stata 8.0. Several 
inconsistencies were detected, and these were mainly related to smoking history. For 
instance, one subject could have answered “no” to ever having smoked, and then later 
stated that he is currently smoking 20 cigarettes per day. All detected inconsistencies 
were investigated and sought solved by re-checking the paper records, and also using 
the recorded data from the postal questionnaire. Some subjects were also contacted by 
phone for clarification. Solved inconsistencies were updated both in GenNet and in the 
paper records. Unsolvable inconsistencies were marked as missing values when the 
variable in question was non-essential. Unsolvable inconsistencies involving essential 
variables (variables concerning the inclusion/exclusion criteria of a subject) would 
lead to an exclusion from the study. A total of 23 subjects were excluded in this 
process. 
Statistics 
All statistical analyses were performed using the Stata/IC statistical package, releases 
8-10 (StataCorp LP, College Station, TX, USA). In all three papers proportions were 
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tested using Pearson’s χ2-test (39). Normally distributed variables were tested using 
one way analysis of variance (ANOVA) and reported with means and standard 
deviations (SD). Not normally distributed variables were tested using the Kruskal-
Wallis test (40) and reported with medians and 25 and 75 percentiles. A significance 
level of 0.05 was applied for all tests. 
In papers I and III a multiple linear regression model was used to examine the 
relationship between the dependent and independent variables. In paper I, the %LAA-
values were log-transformed using the natural logarithm, because both the %LAA-
values and the resulting regression residuals were right-skewed. In paper I, the results 
from the whole multiple linear regression model was reported as the regression 
coefficient for each explanatory variable, along with the standard errors (SE), p-values, 
intercept and the adjusted R2. In paper III, only the coefficients and SE for the main 
explanatory variables (%LAA and AWT-Pi10) were reported, along with the adjusted 
R2 and a list of the adjustments or covariates used in the model. The regression 
coefficient was regarded as statistically significant if the 95 % confidence interval (95 
% CI) did not include 0. 
 In paper II, the dichotomous respiratory symptom outcomes were examined using a 
multiple logistic regression model, while the ordinal dyspnea measure (MRCDS) was 
examined using a multiple ordinal logistic regression model (41). The results of the 
multiple logistic regression models were reported as odds ratios (OR) with a 95 % CIs 
for the main explanatory variables (%LAA and AWT-Pi10), along with the adjusted 
R2 and a list of adjustments or covariates used in the model. The ORs were regarded as 
statistically significant if the 95% CI did not include 1. 
Multiple regression analysis, both linear and logistic, allows for adjustment for 
confounding factors using covariates. In all regression models adjustments were made 
for sex, age and smoking history (both current and number of pack-years). Although 
every CT scan was supposed to be taken at suspended full inspiration, the level of 
inflation might have varied between subjects. Consequently, all regression models 
were also adjusted for inflation level (CT measured total lung volume divided by the 
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predicted total lung capacity (42)). Other adjustments were also used when specified, 
including FEV1 in percent predicted, DLCO, body mass index (BMI), HbCO and co-
morbid heart disease. We also tested for some potential interactions between sex, age, 
smoking and the main explanatory variables (%LAA and AWT-Pi10) as specified in 
each paper. The analyses were mainly run separately for COPD and non-COPD 
subjects, but some additional analyses were run on the whole sample to check for 







Synopsis of papers 
Paper I 
Quantitative computed tomography: emphysema and airway wall thickness by sex, age 
and smoking 
COPD is a complex disorder characterized by chronic airflow limitation. The 
underlying cause of this airflow limitation is a mixture of small airway disease 
(obstructive bronchiolitis) and parenchymal destruction (emphysema). COPD is 
usually assessed by spirometry, which is an integral part of both the definition and the 
classification of COPD. But spirometry alone cannot differentiate between the 
underlying causes of this airflow limitation. Quantitative CT can be used to quantify 
these underlying causes, and to assess the relative contribution of airway disease and 
emphysema. There is limited data available on how these quantitative CT measures 
vary with age, gender and smoking history. 
The aim of this study was to quantify the CT measured emphysema (%LAA) and 
airway wall thickness (AWT-Pi10) in a large COPD patient register and community 
based sample of ever-smokers, and to determine how these anatomic variables 
interacted with gender, age and smoking history. 
The median (25, 75-percentile) %LAA was higher in COPD subjects (7.0 (2.2, 17.8)) 
than in non-COPD subjects (0.5 (0.2, 1.3)), and higher in men than in women, 
regardless of COPD status. The mean (SD) AWT-Pi10 (cm) was higher in COPD 
subjects (0.51 (0.03)) than in non-COPD subjects (0.47 (0.03)), and higher in men than 
in women, regardless of COPD status. The %LAA increased with increasing age in 
both COPD and non-COPD subjects, while AWT-Pi10 decreased slightly with 
increasing age in COPD subjects only. %LAA was higher in ex-smokers than in 
current smokers, and increased slightly with number of pack years. This pattern was 
seen regardless of COPD status. The AWT-Pi10 increased with higher daily cigarette 
consumption and increasing number of pack years in both COPD and non-COPD 
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subjects. The multiple linear regression analyses including adjustments for gender, age 
and smoking confirmed the above mentioned crude relationships. Interaction analysis 
revealed that %LAA increased more rapidly with increasing age in female than in 
male non-COPD subjects. Interaction analyses also revealed that among COPD 
subjects %LAA increased more rapidly with increasing age in current smokers, and 
that AWT-Pi10 increased more rapidly with increasing number of pack years in non-
COPD subjects than in COPD subjects. 
In conclusion, we found significant differences between COPD and non-COPD 
subjects in quantitative CT measures of emphysema and airway wall thickness. We 
also found that gender, age and smoking history have strong effects on these 
quantitative CT measures and must be considered when comparing quantitative CT 
studies. 
Paper II 
Quantitative computed tomography measures of emphysema and airway wall thickness 
are related to respiratory symptoms 
The diagnosis of COPD is usually made by spirometry, but respiratory symptoms are a 
very important part of the clinical picture. Quantitative CT can be used to assess the 
pathological changes in lung structure associated with COPD, and to separate different 
subtypes of COPD according to the contribution of airways disease and emphysema. 
Quantitative CT measurements have been shown to be significantly correlated with 
spirometric values, but spirometry alone cannot explain the whole variation of the 
quantitative CT measurements. Previous studies have shown that there is an 
association between respiratory symptoms and quantitative CT measures of 
emphysema and airway wall thickness, but these studies were either very small, or did 
not fully adjust for pulmonary function or other possible confounders. Hence, there is 




The aim of this study was to describe the relationship between respiratory symptoms 
of COPD and quantitative CT measures of emphysema and airway wall thickness, and 
to assess how these relationships interacted with COPD-status, gender, age and 
smoking history. 
About 15% of the non-COPD subjects reported at least dyspnea grade 2 in the 
MRCDS, while the corresponding figure among the COPD subjects was 70%. The 
cough, phlegm and wheezing symptoms were 2-5 times more frequent in those with as 
in those without COPD. In both groups dyspnea grade 2 or above and wheezing was 
reported more often by women than men, while phlegm was more frequently reported 
by men. Crude analyses showed that the MRCDS increased with increasing level of 
%LAA in COPD subjects only, while the airway wall thickness did not significantly 
affect the degree of dyspnea. We found more emphysema and thicker airway walls in 
the subjects who answered yes to the cough and wheezing attack questions, but these 
differences were not always significant. In the multivariate analyses adjusted for 
gender, age, smoking and level of inflation, the above mentioned crude relationships 
mainly persisted, but some relationships gained and some lost significance. The odds 
for increased dyspnea was increased by an estimated factor of 1.87 per 10% increase 
in %LAA among COPD subjects, while none of the other respiratory symptoms varied 
significantly with level of emphysema in the multivariate model. Increasing AWT-
Pi10 was significantly associated with increased dyspnea level and presence of 
morning and chronic cough symptoms among the COPD patients, and significantly 
related to wheezing among both COPD and non-COPD subjects in the multiple 
logistic regression analyses. Adding FEV1 to the multivariate models did not alter the 
observed relationships. Combined analysis of %LAA and AWT-Pi10 in the same 
model showed that both quantitative CT measures were independently associated with 
MRCDS. 
In conclusion, we have shown that quantitative CT measures of emphysema and 
airway wall thickness are significantly and independently associated with respiratory 
symptoms, and may be used to explain the presence of respiratory symptoms beyond 




Quantitative CT measures of emphysema and airway wall thickness are related to 
DLCO 
The observed airflow limitation in COPD patients is caused by a mixture of small 
airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), 
but neither spirometry nor DLCO can adequately separate between these two 
conditions. Quantitative CT is an increasingly used method to assess COPD related 
changes in the lung structure, including the airway wall thickening associated with 
small airway disease and the reduced parenchymal density associated with 
emphysema. The association between these quantitative CT measures and spirometric 
values is well documented in the literature, while there is limited knowledge on the 
relationship between DLCO and quantitative CT measurements. 
The aim of this study was to examine the relationship between the diffusing capacity 
of the lung and quantitative CT measures of emphysema and airway wall thickness, 
and to assess how these relationships varied by COPD status, gender, age and smoking 
history. 
The non-COPD subjects had higher absolute and percent predicted values of DLCO, 
VA and DLCO/VA. Men had higher absolute values of DLCO and VA in both COPD 
and non-COPD subjects. In percent of predicted values, the women had higher values 
for DLCO/VA, especially among COPD subjects. Crude analyses showed that 
increasing level of both %LAA and AWT-Pi10 were significantly associated with 
decreasing and increasing level of DLCO, respectively, in both COPD and non-COPD 
subjects (p < 0.01). DLCO/VA also decreased significantly with increasing level of 
%LAA (p<0.0001) in both COPD and non-COPD subjects, while there was no 
association between AWT-Pi10 and DLCO/VA. Multiple linear regression analyses 
adjusted for gender, hemoglobin concentration, age, height, pack years, current 
smoking, FEV1 in percent of predicted and inflation level showed that %LAA was 
consistently and negatively associated with both DLCO and DLCO/VA in COPD 
subjects. The observed associations of %LAA were less consistent in the non-COPD 
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group, and not significant in the fully adjusted model. Using the same model and 
adjustments, we found a significant and positive association between AWT-Pi10 and 
DLCO in both COPD and non-COPD subjects, but significance was lost after adjusting 
for inflation level in the non-COPD group. We did not find a significant association 
between AWT-Pi10 and DLCO/VA in the multiple linear regression analysis. The 
explained variation (adjusted R2) attributable to %LAA was 16% in the adjusted DLCO 
model and 26% in the adjusted DLCO/VA model among COPD subjects,, while it was 
negligible among non-COPD subjects. The explained variation attributable to AWT-
Pi10 was very small (0-2%) in all models. Interaction analysis of the COPD subjects 
revealed that there was a stronger negative relationship between %LAA and DLCO in 
men than in women. 
In conclusion, we have shown that quantitative CT measures of emphysema are highly 
related to both diffusing capacity and diffusing coefficient, and that this relationship is 
even stronger in men. We have also shown that there is a positive, but not equally 
strong, relation between CT measured airway wall thickness and diffusing capacity, 










All study participants were part of the GenKOLS study, which was a large 
case/control-study primarily designed to look for genetic risk factors of COPD in ever-
smokers aged 40 years or older. The examination of quantitative CT measurements 
and their relation to age, sex, smoking, respiratory symptoms and pulmonary function 
were secondary study objectives. Furthermore, the quantitative CT studies included in 
this thesis did not use the classical case-control approach of comparing the cases and 
controls, but rather an observational approach to the two separate groups of subjects 
with and without COPD. The study was cross-sectional in design. We were therefore 
limited to describing associations and relationships between variables, and no valid 
inferences could be made about cause and effect. 
Reliability 
The terms reliability and validity are crucial when it comes to determining whether or 
not to trust your findings (43, 44). A test is considered reliable when there is 
reasonable agreement between replicate measurements using that test. The 
measurements of a reliable test will consequently have a small spread, but do not 
necessarily measure the “correct” or “true” value. A high reliability is a prerequisite 
for a high validity, but no guarantee.  
This thesis presents data on pulmonary function (spirometry and diffusing capacity), 
smoking habits, respiratory symptoms and quantitative CT measurements.  
The pulmonary function tests were performed using standardized equipment 
(Appendix F, G), and following the current ATS guidelines (3, 34). The reliability of 
the pulmonary function tests was therefore not perceived as a problem. 
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Smoking habits and respiratory symptoms were assessed using questionnaires. This 
kind of self-reported data may be vulnerable to inaccuracies due to the subjects’ 
memory and perception of the question, but also due to poor data handling afterwards. 
Every precaution was taken to ensure correct data handling, and the wording of the 
questions used was based on previously validated studies (45, 46). The reliability of 
the questionnaire data was not perceived as a problem. 
The CT images were acquired using standardized equipment, and the scanner was set 
up using air and water phantoms according to the manufacturer’s recommendations. 
The reliability of the acquired CT images was therefore not perceived as a problem, 
and due to the associated risk of radiation, internal repeatability tests were not 
performed. 
The quantitative assessment of the CT images was to a certain degree operator 
dependent. But there were only a few highly trained operators, and the operator input 
was minimal with regard to the parenchymal density and volume measurements. We 
performed analyses of a randomized sub-sample of 20 subjects, whose CT images 
were quantitatively assessed by two different operators (Figure 3). This analysis 
showed good correlation between the two operators’ measurements, and a mean 





Figure 3 Inter-operator variability (%LAA), Bland-Altman plot (19 subjects) 
The airway measurements are more operator-dependent, due to the selection of eligible 
airways, and one would expect a slightly larger inter-operator variability on these. 
Unfortunately, we do not have enough available data to present a Bland-Altman plot 
for the airway measurements, but a preliminary analysis of 3 subjects indicated an 
inter-operator variability of approx. 2 %. As the operators were blinded to other data 
concerning the subjects, it is reasonable to assume that any misclassification of the 
airway measurements was non-differential, and consequently the observed 
associations would have been even stronger without this potential error. The reliability 
of the quantitative CT assessments was therefore not perceived as a problem. 
Validity 
The validity of a test concerns to which degree a test is actually measuring what it is 
intended to measure (43, 44). Validity can be divided into internal and external 
validity. The internal validity of a study concerns the ability to draw valid conclusions 













Average of Operator1 and Operator2
1/19 =   5.26% outside the limits of agreement
Mean difference  0.001
95% limits of agreement (-0.018, 0.021)
Inter-operator variability (%LAA), Bland Altman plot
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random errors, systematic errors and confounding. The external validity of a study 
concerns the ability to draw valid conclusions about a larger population based on the 
results of the study. The external validity is compromised if the study population is not 
representative of the target population. 
Given the size of this study, random errors were not perceived as a problem. 
Systematic errors, or biases, are independent of study size, and cannot be ruled out.  
A large fraction of the invited (43 %) and included (57%) subjects in this study were 
sampled from population based cohorts with high attendance rates (47, 48). However, 
we also invited/included subjects from the HUH COPD registry (51 % / 38 %) and 
volunteers (6 % / 5 %). The subjects from the COPD registry are not population based, 
and although the volunteers did not differ much from the population based subjects, 
their motives for participating are not known. This study design with recruitment from 
several sources, made this study vulnerable to selection bias (49). 
Furthermore, only one half (951 of 1909) of the GenKOLS population underwent a CT 
examination, and this selection was not randomized. Due to the potential radiation risk 
associated with CT, this examination was optional, and offered to included GenKOLS 
subjects until we had included approximately 500 cases and 500 controls with CT. 
This may also have introduced a selection bias. However, there were no large 
differences between the subjects with and without CT with regards to gender, age, 
smoking and FEV1 in percent predicted (Table 3). 
 
 Table 3 Comparison of GenKOLS subjects with and without CT 
   
GenKOLS (All) GenKOLS (no CT) CT sample 
    Non-COPD COPD   Non-COPD COPD   Non-COPD COPD 
n 955 954 467 491 488 463 
Male (%) 50 61 47 58 53 65 
Age (Mean) 56 65 56 67 56 64 
Currently smoking(%) 41 47 40 44 42 49 
Pack-years (Median) 16 28 16 29 16 27 
FEV1% pred (Mean)   95 51 95 49 95 53 
55 
 
There was 4797 invited subjects in this study, but only 2984 (62 %) attended the 
screening visit at HUH. This may have introduced a non-response bias, but a previous 
population study from Hordaland have shown that increasing the response rate from 65 
% to 89 % did not affect the relationship between smoking and lung disease (50).  
Confounding may arise when investigating an association between an exposure and an 
outcome, and both the exposure and outcome are strongly associated with a third 
(known or unknown) variable (43). In multivariate regression models, known 
confounders can be adjusted for. We have included sex, age, smoking and several 
other factors in our regression models, in an attempt to control for potential 
confounders. However, this study only included smokers with at least 2.5 pack-years. 
We were therefore unable to fully adjust for smoking, and cannot rule out that there is 
some residual confounding from smoking. 
Diffusing capacity guidelines 
According to the current ATS guidelines for accurate measurements of diffusing 
capacity (34), a test should be rejected if the measured inspired vital capacity is less 
than 90% of the largest previously measured FVC. This was the case in 148 subjects in 
the current study. Despite the guidelines, these subjects were not excluded from the 
study. However, it has previously been shown that it is acceptable to include subjects 
with an IVC/FVC-ratio < 90% as long as the characteristics of these subjects do not 
differ much from those with a ratio > 90% (51). As shown in Table 4, there were 
slightly more women and fewer current smokers among the non-COPD subjects in the 
low ratio group compared to the high ratio group. Otherwise there were no large 





Table 4 Comparison of subjects with an IVC/FVC ratio over / under 90 % 
 
IVC/FVC > 90% IVC/FVC < 90% 
    Non-COPD COPD   Non-COPD COPD 
n 332 233 93 55 
Male (%) 56 70 47 71 
Age (Mean) 56 63 53 64 
Currently smoking (%) 51 49 40 56 
Pack-years (Median) 16 26 16 26 
FEV1% pred (Mean)   95 59   97 61 
 
Radiation issues 
In order to perform quantitative CT analyses, one must first acquire a CT image. And 
with the acquisition of this CT image, comes the unavoidable radiation risks that 
accompany any X-ray examination, and especially so with CT. While the standard 
chest radiography only exposes the subject to a radiation dose equivalent of approx. 3 
days of average natural background radiation, the radiation dose from a chest CT is 
approx. 350 times higher, or the equivalent of more than 1000 days of background 
radiation (52). There is still incomplete knowledge about the complex link between 
ionizing radiation exposure and adverse future effects in humans, but even the 
relatively low radiation doses associated with a chest CT (approx. 7 mSv) carries an 
increased risk of cancer (53). This risk is probably cumulative, and higher in younger 
people, women and in certain tissues (e.g. breast and thyroid).  And however low this 
risk may be, there is general consensus that one should keep this exposure to a 
necessary minimum. And when a CT is warranted, the examination should involve as 
little radiation as possible, while maintaining the image quality. Fortunately, newer 
techniques and equipment have made it possible to achieve better image quality using 
lower radiation doses. With regard to quantitative CT measures of the chest, one can 
achieve acceptable images from the lung parenchyma using very low radiation doses, 




Quantitative CT analyses 
 There are many different approaches to quantitative CT analysis, and some 
controversies, especially with regard to airway analysis. But all these approaches are 
similar in their use of acquired CT images to obtain measurements of lung volume and 
X-ray attenuation or density measured in Hounsfield units. The measurements of lung 
volumes are done by using different lung segmentation algorithms. These algorithms 
have become very precise, and there is general consensus that supine lung volume can 
be accurately measured using quantitative CT measurements (56). 
Parenchymal analysis 
The X-ray attenuation values obtained from the CT images gives in indication of the 
density of the lung, as the HU scale is proportional to the density within the biological 
range. These density measurements must then be summarized in a way that gives a 
reasonable estimate of the phenotype in question (emphysema). The two most 
common ways of doing this are the density mask threshold cut-off and the percentile 
methods, and both approaches have been shown to correlate with the extent of 
emphysema in corresponding pathological samples (12, 13). Both methods have been 
accepted by the scientific community, and the remaining debate concerns which 
density cut-off, or which percentile to use. In the current study we have chosen the 
density mask approach, with the most commonly used threshold cut-off value (-950 
HU). This was a cross-sectional design, and we could have used either method, but for 
longitudinal data it is recommended that one uses the percentile method (15th perc), as 
this method is less sensitive to minor changes in the technical aspects of the CT scan 
and more sensitive to structural changes (56). These technical aspects (type of scanner, 
X-ray exposure settings, image noise, reconstruction algorithms) can greatly influence 
the amount of emphysema measured. It is therefore very important to keep these 
aspects as constant as possible, especially in longitudinal studies, but also for 
comparison of different cross-sectional studies. Another important influence on the 
amount of emphysema measured is the degree of inhalation during the CT scan. This 
can be controlled using spirometric gating, but that is not very practical. It is therefore 
recommended, especially in longitudinal studies, that one use a mathematical 
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adjustment based on the CT measured lung volume (17). In the multiple regression 
analyses presented in the current study, we used the CT measured lung volume divided 
by the predicted TLC to adjust for this. 
Airway analysis 
The characteristic airflow limitation seen in COPD is in large part due to airway 
remodeling in the small airways (< 2 mm in diameter) (7, 57), and non-invasive 
measures of these small airways is of great interest. However, CT images, and 
consequently quantitative CT analyses of the airways, has a limited resolution, both in 
pixel size and slice thickness. The field of view in each slice limits the pixel size to 
approx. 0.5 mm, and although some of the newest multi-slice scanners can acquire 
images with a slice thickness as thin as 0.5 mm, most scanners in a clinical setting are 
limited to a slice thickness of 1.0-1.25 mm. Due to these resolution limitations, 
airways smaller than 2 mm in diameter cannot be accurately measured using 
quantitative CT, and the technology is limited to measuring airways > 2 mm in 
diameter. However, it has been shown that the remodeling in the small airways can 
also be seen in larger airways, and that measurements of these larger airways can be 
used as a surrogate for the processes occurring in the smaller airways (24). This 
correlation gets stronger the smaller (more distal) the measured airway is, so that a 6th 
generation airway correlates better than a 3rd generation airway (58, 59). In the current 
study we used a slice-gap approach, and could therefore not classify the airways into 
generations. Newer approaches use contiguous scans to produce a three-dimensional 
airway three, enabling measurements from airways with known generations. This new 
approach bears promise of a more precise airway assessment, and an even stronger 
correlation with the small airways actually responsible for the airflow limitation. 
An accurate localization of the transitions between airway lumen, airway wall and the 
surrounding parenchymal tissue is a key element in quantitative CT assessment of the 
airways. This process gets more difficult when the size of the structures you are 
measuring (e.g. the airway wall) borderlines the point spread function (also known as 
the “partial volume effect”) of the scanner, resulting in blurring and inaccurate 
measurements. Several approaches and reconstruction algorithms have been applied to 
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overcome this problem, one of the first being the “full-width at half-maximum” 
method (23, 60), which we used in this study. A known problem with this approach is 
the overestimation of the airway wall, and the underestimation of the airway lumen, 
and this problem increases with decreasing airway size (22, 60). Several alternative 
algorithms have therefore been developed, and examples of these are the “maximum-
likelihood method” (22), the “score-guided erosion algorithm” (21) and the “elliptical 
fit algorithm” (61). While each approach has some advantages, there is no solid 









Discussion of the results 
Several topics regarding the results from the current study have already been discussed 
in the discussion sections of Papers 1-3, and they will not be repeated here. The focus 
of this section will be on topics that were not discussed thoroughly in the respective 
papers. 
Pre- versus post-bronchodilator CT 
In accordance with the current GOLD guidelines (2) , we used post-bronchodilator 
spirometric values to classify the subjects included in this study. Furthermore, we used 
post-bronchodilator FEV1 values as an adjustment in the multiple regression analyses. 
The CT images that the quantitative analysis was based on were however not acquired 
after administration of any bronchodilator. There is limited knowledge about the effect 
of bronchodilation on quantitative CT measures, but this difference could potentially 
have influenced our results with regard to both airway dimensions and parenchymal 
density through altered regional ventilation (62). Furthermore, this influence would 
probably have been even stronger in the non-COPD subjects, as many of the COPD 
subjects were already using long acting bronchodilators. The exact effect of this 
difference is not known, but it is reasonable to assume that the observed associations 
would have been even stronger without this potential influence. 
CT versus diffusing capacity: The effect of body position 
CT images are usually (and in the current study) acquired in the supine position 
(although the prone position may also be used), while DLCO is usually (and in the 
current study) measured sitting in an upright position. This positional difference may 
potentially have affected the results of Paper 3. 
The density measurements obtained from a CT scan are dependent on the relative 
amounts of lung tissue, air and blood present in the lung. These components are not 
homogenously distributed throughout the lung, and the relative proportions 
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continuously change during respiration (63). The relative distribution of these 
components is also affected by gravity, and the extent of air trapping follows a 
gravitational gradient with more air trapping in the dependent lung regions (64). This 
effect is less pronounced when CT images are acquired at full inhalation, as was done 
in the current study, but gravity certainly has an effect on the distribution of air and 
blood. 
It has also been shown that both the pulmonary capillary blood volume and DLCO 
increases in the supine position as compared to an erect position. These effects were 
far more pronounced in patients with the chronic bronchitis phenotype as opposed the 
emphysematous phenotype, and the effect decreased with increasing age (65, 66). 
As the current study population was relatively old, the difference in body position has 
probably not affected the observed relationship between %LAA and DLCO. We cannot 
rule out the possibility that the difference in body position may have influenced the 
observed relationship between AWT-Pi10 and DLCO, but there are no indications that 
CT measured airway dimensions are affected by body position. 
CT assessed emphysema and airway wall thickness versus 
respiratory symptoms  
Our study showed that level of emphysema and airway wall thickness was related to 
dyspnea, while airway wall thickness was related to cough, phlegm and wheezing. 
These findings help to provide a clinical correlate to level of emphysema and airway 
wall thickness. This is important as the patient does not sense the emphysema or the 
airway wall dimensions. It also enables the clinician to interpret the CT findings and to 
put them into a clinical context. It is important to the researcher as our observations 
imply that the CT assessment may be used to describe potential phenotypes of COPD 
(8).   
The cough and wheezing symptoms were assessed as dichotomous variables.  This is a 
rough way of recording the symptoms and will probably work to underestimate the 
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strength of the relationship between respiratory symptoms and the quantitative CT 
measures. Dyspnea was also assessed as a categorical, but ordinal variable. The 
perception of the symptoms also may influence on their relationships to the CT 
findings. We have no information as to what extent differences in perception of the 
various symptoms influence the observed associations between symptoms and 
quantitative CT measures. 
Dyspnea, cough and wheezing may be seen in other conditions than COPD, as for 
instance coronary heart disease, cardiac heart failure and asthma. All of these 
conditions may be related to COPD, and we adjusted for some of these conditions. 
However, the information indicative of these diseases was self-reported. If more valid 
information about these co-morbidities had been available and added to the equation, 
one may speculate that more specific relationships between respiratory symptoms and 
quantitative CT measures would have been observed than was actually the case.  
The technology and data handling available at the time of the present study did not 
allow us to assess the level of bronchial generation studied. Up to date technology in 
CT allows the researcher to generate a three-dimensional bronchial tree, and estimate 
the generation of the measured bronchia down to the sixth generation bronchus (67). 
This allows a more precise characterization of the airways than we have been able to 
perform in the current study. This new technology will hopefully work to further 
clarify the relationship between the airway wall dimensions and the respiratory 
symptoms. 
A final comment to the relationship between the CT findings and the respiratory 
symptoms has to do with the study design. As the current study is a cross sectional 
survey, it offers only one point of time in this relationship. A longitudinal study would 
have allowed another perspective of the association between symptoms and CT 
findings. One may speculate that the observed relationships then would have been 
stronger than what was observed cross-sectionally. However, from a clinical point of 




CT assessed emphysema and airway wall thickness by gender and 
smoking 
As the first study we observed that smoking is related to airway wall dimensions 
(Paper I). When evaluating these results it is important to bear in mind that other 
potential risk factors of COPD have not been taken into account. Examples of such 
factors include occupational airborne exposure, impaired socio economic status and 
poor indoor air quality. These risk factors are also related to cigarette smoking and 
may act as confounders in the relationship between smoking and the CT measured 
airway wall dimensions. They may theoretically also interact with smoking 
aggregating its effect on the airway wall measurements.  
Several studies have observed a stronger relationship between smoking and the 
pulmonary outcome variables in women than in men (68, 69). One interpretation has 
been that women are more susceptible to smoking than men (70). The pulmonary 
outcomes have mainly been respiratory symptoms and quality of life assessments. 
Hence, gender differences in perception of these outcomes could explain these 
dissimilarities between men and women. Level of emphysema and airway wall 
dimensions are beyond perception. Our findings do not support the hypothesis that 
women are more susceptible to smoking than men. On the other hand we used self-
reported information on both current smoking status and total smoking consumption. 
This might have worked to obscure any gender difference in the effect of smoking. 
Recent data suggest that there are biological mechanisms indicating increased 
susceptibility of COPD in female smokers (71, 72).     
The lower airways are not sterile, and culture independent molecular methods have 
shown that the microbiota of humans is far greater in extent than previously 
recognized (73). Symbiotic bacteria like Bacteriodetes and Firmicutes elicit tonic 
signals in the gut epithelium that prevent activation of innate and adaptive immune 
responses (73, 74), and symbiotic bacteria down regulate immune responses to 
pathogens in the nasal mucosa (75). It is possible that similar mechanisms may be 
operational in healthy airways. 
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It is not known if smoking may influence the distribution and relative content of 
symbiotic and pathogenic bacteria in the airways, but smoking is related to thicker 
airway walls. One may speculate that at least part of this effect may be due to the 
influence of smoking on the airway microbiome. 
When interpreting the observations of the current study it is important to bear in mind 
that it is cross sectional in design. As such, we are not able to take into account any 
cohort effects or any influence of different time periods. In a cross sectional setting 
any difference between a 40 years old and an 80 years old subject may be interpreted 
as being due to the age. To be able to examine the cohort and period effects, a 







This study has shown that COPD subjects and men have significantly more 
emphysema and thicker airway walls than non-COPD subjects and women. 
Furthermore, both these quantitative CT measures are substantially affected by age and 
smoking habits. This has not previously been shown in a large study like this, and it 
underlines the importance of taking gender, age and smoking habits into account when 
designing and interpreting these kinds of studies. 
This study has also shown that these quantitative CT measures are strongly and 
independently associated with respiratory symptoms, and that they may be used to 
explain respiratory symptoms beyond the information that is available from a 
spirometry. 
This study has also confirmed our hypothesis that CT measured emphysema is highly 
related to diffusing capacity, and that this relationship is even stronger in men. The 
finding of a significant and positive relationship between diffusing capacity and 









1. The analyses of this thesis are based on cross sectional study design. It would be of 
interest to examine the relationships of gender, age and smoking to level of 
emphysema and airway wall thickness in a longitudinal study design. Such a study 
would give a more valid estimate of these relationships than offered by a one point 
in time examination. 
2. A similar consideration as above can be made for the associations between the 
quantitative CT variables and the respiratory symptoms. 
3. Longitudinal data on the development of emphysema and airway wall thickness in 
terms of distribution and degree will improve our knowledge of the natural history 
of COPD and its phenotypes. A further objective would be to examine predictors 
for these developments. 
4. Apart from smoking, limited data is available on how other airborne exposures like 
occupational airborne exposure and indoor air pollution including passive smoking 
affect the level of emphysema and airway wall thickness. As CT is increasingly 
used to characterize patients with COPD both in the clinic and in research, data on 
the relationship between CT findings and other airborne exposures than smoking is 
warranted. 
5. Limited data is available regarding the prognostic value of these quantitative CT 
variables. This particularly relates to the airway wall thickness. Such knowledge 
will work to improve the clinical validity of the CT findings. This goes for both 
subjects with and without COPD. 
6. Improvements in both CT technology and data handling in the years to come will 
enable the use of quantitative CT to better characterize the anatomical correlates of 
for instance respiratory symptoms. One may also be able to examine the 
generations of the bronchial tree more specifically than it is done today.  
7. Little is known regarding the use of these quantitative CT variables in combination 
with other COPD key variables like spirometry, exercise capacity, exacerbation 
rates or inflammatory markers in the characterization of phenotypes of COPD.  
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8. We defined COPD based on the GOLD criteria. It would be interesting to examine 
how the observed relationship in this thesis would be affected if COPD had been 





a) Methods sections of Papers I, II and III 
In all three papers, it was specified that we used a slice thickness of 1.0 mm at 
20 mm intervals when acquiring the CT images. This is incorrect. The actual 
slice thickness used was 1.25 mm at 20 mm intervals. The error was due to a 
misunderstanding in an early phase of the project, and was not discovered until 
June 2011. However, this error has had no consequences with regard to the data 
presented in the three papers, as the error was in the description only, and the 
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